Skip to content
All Podcasts – Lifestyle
Author:
Vector Sciences & Therapeutics
Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
July 24, 2026
Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels
July 21, 2026
Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist
July 17, 2026
Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies
July 15, 2026
Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio
July 7, 2026
Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform
June 30, 2026
Gary Payton II Named Chief Athletic Ambassador of Valor
June 22, 2026
Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform
June 12, 2026
Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor
June 8, 2026
Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy
June 2, 2026
1
2
Next Page
→